Molecular Profile |
Indication/Tumor Type |
Response Type |
Relevant Treatment Approaches |
Therapy Name |
Approval Status |
Evidence Type |
Efficacy Evidence |
References |
ERBB2 G776delinsVC
|
lung adenocarcinoma
|
predicted - sensitive |
HER inhibitor (Pan)
|
Poziotinib
|
Phase II |
Actionable |
In a Phase II trial, Poziotinib (HM781-36B) treatment resulted in 1 partial response and 1 stable disease in 2 patients with lung adenocarcinoma harboring ERBB2 (HER2) G776delinsVC (PMID: 30149884; NCT02979821).
|
30149884
|
ERBB2 G776delinsVC
|
non-small cell lung carcinoma
|
conflicting |
HER inhibitor (Pan)
|
Afatinib
|
Clinical Study |
Actionable |
In a retrospective study, Gilotrif (afatinib) treatment resulted in an objective response rate of 0% (0/3) in non-small cell lung cancer patients harboring ERBB2 (HER2) G776delinsVC (PMID: 30527195).
|
30527195
|
ERBB2 G776delinsVC
|
non-small cell lung carcinoma
|
conflicting |
HER inhibitor (Pan)
|
Afatinib
|
Preclinical - Cell line xenograft |
Actionable |
In a preclinical study, Gilotrif (afatinib) inhibited proliferation and induced cell-cycle arrest and apoptosis of a non-small cell lung cancer (NSCLC) cell line harboring ERBB2 (HER2) G776delinsVC in culture and inhibited tumor growth in NSCLC cell line xenografts carrying ERBB2 (HER2) G776delinsVC (PMID: 26545934).
|
26545934
|
ERBB2 G776delinsVC
|
Advanced Solid Tumor
|
sensitive |
HER inhibitor (Pan)
|
Afatinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Gilotrif (afatinib) inhibited growth of transformed cells expressing ERBB2 (HER2) G776delinsVC in culture (PMID: 30527195).
|
30527195
|
ERBB2 G776delinsVC
|
non-small cell lung carcinoma
|
no benefit |
HER2 Inhibitor
|
Neratinib
|
Phase II |
Actionable |
In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in stable disease with a progression-free survival of 8.5 months in a patient with non-small cell lung cancer harboring ERBB2 (HER2) G776delinsVC (PMID: 29420467; NCT01953926).
|
29420467
|
ERBB2 G776delinsVC
|
Advanced Solid Tumor
|
sensitive |
HER2 Inhibitor
|
Neratinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Nerlynx (neratinib) inhibited growth of transformed cells expressing ERBB2 (HER2) G776delinsVC in culture (PMID: 30527195).
|
30527195
|
ERBB2 G776delinsVC
|
non-small cell lung carcinoma
|
predicted - sensitive |
HER inhibitor (Pan)
|
Poziotinib
|
Clinical Study |
Actionable |
In a retrospective study, Poziotinib (HM781-36B) treatment resulted in an objective response rate of 50% (1/2) in non-small cell lung cancer patients harboring ERBB2 (HER2) G776delinsVC (PMID: 30527195).
|
30527195
|
ERBB2 G776delinsVC
|
Advanced Solid Tumor
|
sensitive |
|
AZ5104
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, AZ5104 inhibited growth of transformed cells expressing ERBB2 (HER2) G776delinsVC in culture (PMID: 30527195).
|
30527195
|
ERBB2 G776delinsVC
|
Advanced Solid Tumor
|
resistant |
HER2 Inhibitor
|
Tucatinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, transformed cells expressing ERBB2 (HER2) G776delinsVC were resistant to Tucatinib (ARRY-380) in culture (PMID: 30527195).
|
30527195
|
ERBB2 G776delinsVC
|
lung cancer
|
no benefit |
|
Gefitinib
|
Preclinical |
Actionable |
In a preclinical study, bronchial epithelial cells expressing ERBB2 (HER2) G776delinsVC did not demonstrate sensitivity to Iressa (gefitinib) in culture (PMID: 26545934).
|
26545934
|
ERBB2 G776delinsVC
|
Advanced Solid Tumor
|
predicted - sensitive |
|
Ganetespib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Ganetespib inhibited growth of transformed cells expressing ERBB2 (HER2) G776delinsVC in culture (PMID: 30527195).
|
30527195
|
ERBB2 G776delinsVC
|
Advanced Solid Tumor
|
sensitive |
HER inhibitor (Pan)
|
Poziotinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Poziotinib (HM781-36B) inhibited growth of a transformed cell line expressing ERBB2 (HER2) G776delinsVC in culture (PMID: 29686424).
|
29686424
|
ERBB2 G776delinsVC
|
Advanced Solid Tumor
|
sensitive |
|
Osimertinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Tagrisso (osimertinib) inhibited growth of transformed cells expressing ERBB2 (HER2) G776delinsVC in culture (PMID: 30527195).
|
30527195
|
ERBB2 G776delinsVC
|
Advanced Solid Tumor
|
sensitive |
HER2 Inhibitor
|
Pyrotinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Pyrotinib inhibited growth of transformed cells expressing ERBB2 (HER2) G776delinsVC in culture (PMID: 30527195).
|
30527195
|
ERBB2 G776delinsVC
|
Advanced Solid Tumor
|
decreased response |
|
Erlotinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, transformed cells expressing ERBB2 (HER2) G776delinsVC demonstrated decreased response to Tarceva (erlotinib) compared to Poziotinib (HM781-36B) in culture (PMID: 30527195).
|
30527195
|
ERBB2 G776delinsVC
|
Advanced Solid Tumor
|
predicted - sensitive |
|
Luminespib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Luminespib (AUY922) inhibited growth of transformed cells expressing ERBB2 (HER2) G776delinsVC in culture (PMID: 30527195).
|
30527195
|
ERBB2 G776delinsVC
|
Advanced Solid Tumor
|
sensitive |
HER inhibitor (Pan)
|
Dacomitinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Vizimpro (dacomitinib) inhibited growth of transformed cells expressing ERBB2 (HER2) G776delinsVC in culture (PMID: 30527195).
|
30527195
|
ERBB2 G776delinsVC
|
lung cancer
|
sensitive |
HER inhibitor (Pan)
|
Afatinib
|
Preclinical |
Actionable |
In a preclinical study, Gilotrif (afatinib) inhibited Erbb2 (Her2) phosphorylation and downstream signaling in bronchial epithelial cells expressing ERBB2 (HER2) G776delinsVC in culture (PMID: 26545934).
|
26545934
|
ERBB2 G776delinsVC
|
non-small cell lung carcinoma
|
no benefit |
|
Erlotinib
|
Clinical Study |
Actionable |
In a retrospective study, Tarceva (erlotinib) treatment resulted in an objective response rate of 0% (0/1) in non-small cell lung cancer patients harboring ERBB2 (HER2) G776delinsVC (PMID: 30527195).
|
30527195
|
ERBB2 G776delinsVC
|
non-small cell lung carcinoma
|
no benefit |
HER inhibitor (Pan)
|
Dacomitinib
|
Clinical Study |
Actionable |
In a retrospective study, Vizimpro (dacomitinib) treatment resulted in an objective response rate of 0% (0/2) in non-small cell lung cancer patients harboring ERBB2 (HER2) G776delinsVC (PMID: 30527195).
|
30527195
|
ERBB2 G776delinsVC
|
Advanced Solid Tumor
|
resistant |
|
Lapatinib
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, transformed cells expressing ERBB2 (HER2) G776delinsVC were resistant to Tykerb (lapatinib) in culture (PMID: 30527195).
|
30527195
|
ERBB2 G776delinsVC
|
non-small cell lung carcinoma
|
resistant |
|
Gefitinib
|
Preclinical |
Actionable |
In a preclinical study, non-small cell lung cancer cells harboring ERBB2 (HER2) G776delinsVC demonstrated resistance to treatment with Iressa (gefitinib) in culture (PMID: 26545934).
|
26545934
|
ERBB2 G776delinsVC
|
lung adenocarcinoma
|
predicted - sensitive |
|
trastuzumab emtansine
|
Clinical Study |
Actionable |
In a Phase II trial, treatment with Kadcyla (trastuzumab emtansine) resulted in best overall responses of partial response in 44% (8/18) and stable disease in 39% (7/18), and median progression-free survival of 5 months in patients with lung adenocarcinoma harboring ERBB2 (HER2) activating mutations, and a subset of patients specifically harboring ERBB2 (HER2) G776delinsVC had a 100% (2/2) partial response rate (PMID: 29989854; NCT02675829).
|
29989854
|
ERBB2 G776delinsVC
|
non-small cell lung carcinoma
|
no benefit |
|
Lapatinib
|
Clinical Study |
Actionable |
In a retrospective study, Tykerb (lapatinib) treatment resulted in an objective response rate of 0% (0/1) in non-small cell lung cancer patients harboring ERBB2 (HER2) G776delinsVC (PMID: 30527195).
|
30527195
|